Downloads: 0 | Views: 84

Informative Article | Pharmacotherapeutics | India | Volume 11 Issue 6, June 2022

Will Dostarlimab Become the New Rectal Cancer Drug of Choice?

Motupalli Sankeerth Kumar ^[2] | Ponnaluri Lalitha ^[2] | Seelam Victor John Wilson

Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.

Keywords: Dostarlimab, Rectal cancer, new drug of choice

Edition: Volume 11 Issue 6, June 2022,

Pages: 1369 - 1369